Building a deeper Harbour

How Harbour BioMed plans pipeline growth after GIC-led $85 million series B

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals.

Singapore sovereign wealth fund GIC led the round, which closed on Aug. 27. Fellow new

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers